----
Current ValuationThe current P/E ratio is -0.48, above the reasonable range, cheaper than 6.67% of the time in the past 1 years, and the industry ranks 154/606, the industry Median -1.86.
-0.477xP/E
$1.64Stock price
$-3.44Earnings per share
-0.477xP/E
Stock price$1.64Earnings per share$-3.44
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.63x
- Typical range
- -0.89x–-0.52x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
021426384
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -59.72x | 150.60% | $193.48B |
MRNAUSModerna | -25.35x | 17.00% | $79.89B |
CSLLYUSCSL Limited | -25.70x | -- | $66.28B |
NTRAUSNatera | -302.72x | 5.57% | $58.23B |
RVMDUSRevolution Medicines | -22.67x | 61.94% | $40.08B |
ROIVUSRoivant Sciences | -98.99x | 146.69% | $26.36B |
BNTXUSBioNTech SE | -11.32x | 19.30% | $22.13B |
INSMUSInsmed | -23.30x | 75.01% | $20.39B |
BBIOUSBridgebio Pharma | -19.37x | 27.81% | $13.40B |
SMMTUSSummit Therapeutics | -14.42x | 19.79% | $12.34B |
MDGLUSMadrigal Pharma | -30.86x | 51.30% | $10.03B |
PCVXUSVaxcyte | -8.94x | 47.91% | $9.51B |
TWSTUSTwist Bioscience | -67.37x | 28.63% | $9.21B |
KYMRUSKymera Therapeutics | -30.74x | 5.24% | $9.21B |
IBRXUSImmunityBio | -8.78x | 151.32% | $8.71B |
CYTKUSCytokinetics | -9.52x | 6.85% | $8.51B |
ARWRUSArrowHead Pharma | -25.61x | 35,923.70% | $8.20B |
SYREUSSpyre Therapeutics | -53.02x | 45.60% | $7.96B |
ABVXUSAbivax SA | -16.50x | 22.99% | $7.67B |
IONSUSIonis Pharma | -12.62x | 49.51% | $7.13B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
